Pharma BD Deal Intelligence
Celgene acquired Impact Biomedicines for up to $7B for fedratinib.
Celgene Corporation is acquiring Impact Biomedicines in a deal valued at up to $7 billion, gaining fedratinib for treatment of myeloproliferative neoplasms…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Celgene acquired Impact Biomedicines for up to $7B for fedratinib.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Impact Biomedicines (this deal) | 2018 | $7.0B | 54 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2018 deals · Celgene Corporation deals · Oncology deals